http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4028666-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bba842fc4d37dfcaced1b55bc0c91c7c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-22 |
| filingDate | 1990-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fc8a862d81301a4161969c10781323f |
| publicationDate | 1992-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-4028666-A1 |
| titleOfInvention | TRICYCLIC COMPOUNDS CONTAINING HETEROATOMES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| abstract | New 19,22-furano derivs. of FR520 of formula (I) are new: where R2 = Me, Et, n-propyl or allyl; R3 = OH or OMe; and Ac = acetyl. (I) are made by conventional acylation of the 20,24,33-trihydroxy cpds.. Reaction is e.g. in pyridine, opt. in the presence of 4-dimethylaminopyridine (A), using acetic anhydride. USE/ADVANTAGE - (I) have immunosuppressive, antiinflammatory and antiproliferative activities and so can be used to treat e.g. transplant rejection; rheumatoid arthritis; multiple sclerosis; diabetes; dermatitis; acne etc.. They can be admin. topically (at a concn. of 1-3%) or systemically at 0.15-1.5 mg/kg/day. (I) also increase the activity, effect and/or sensitivity of other chemotherapeutic agents, e.g. to reduce the normal dose of toxic antineoplastic and cytostatic agents. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109923118-A |
| priorityDate | 1990-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.